References
- Lawrence D, Mitrou F. One-third of adult smokers have a mental illness. Aust NZ J Psychiatry 2009; 43: 177–178
- Chapman S. A questionable inflated estimate of smoking prevalence among mentally ill persons in Australia. Aust N Z J Psychiatry 2008; 42: 646–648
- Australian Bureau of Statistics. 2004 National Health Survey. Summary of results. Canberra: ABS, 2006.
- Australian Bureau of Statistics. 4326.0 Mental health and well-being: profile of adults: summary of results 2007. Canberra: Australian Bureau of Statistics, 2008.
- Conrad P. The medicalization of society. On the transformation of human conditions into treatable disorders. Johns Hopkins University Press, Baltimore 2007
- Goldberg JO, Van Exan J. Longitudinal rates of smoking in a schizophrenia sample. Tobacco Control 2008; 17: 271–275
- National Preventative Health Taskforce. Technical Report No. 2. Tobacco control in Australia: making smoking history. Canberra: Commonwealth of Australia, 2008.
- Jacka FN, Overland S, Stewart R, Tell GS, Bjelland I, Mykletun A. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry 2009; 43: 45–52
- Facchinetti F, Borella P, Sances G, Fiorini L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynaecol 1991; 78: 177–181
- Braun L, Cohen M. Magnesium in: herbs and natural supplements: an evidence-based guide2nd edn. Elsevier, Sydney 2007
- Arthur R. Nutrition notes: magnesium. J Complement Med 2007; 6: 46–55
- Imada Y, Yoshioka S, Ueda T, Katayama S, Kuno Y, Kawahara R. Relationships between serum magnesium levels and clinical background factors in patients with mood disorders. Psychiatry Clin Neurosci 2002; 56: 509–514
- Le Gassicke, J. Tranylcypromine. Lancet 1963; i:269–270.
- Le Gassicke J, Ashcroft GW, Eccleston D, Evans JI, Oswald I, Ritson EB. The clinical state, sleep and amine metabolism of a tranylcypromine (Parnate) addict. Br J Psychiatry 1965; 111: 357–364
- Shopsin B, Kline NS. Monoamine oxidase inhibitors: potential for drug abuse. Biol Psychiatry 1976; 11: 451–456
- Halle MT, Dilsaver SC. Tranylcypromine withdrawal phenomena. J Psychiatr Neurosci 1993; 18: 49–50
- Shakibai SV, Johnson JP, Bourgeois JA. Paranoid delusions and cognitive impairment suggesting Fahr's disease. Psychosomatics 2005; 46: 569–572
- Boyer EW, Shanon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112–1120
- Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003; 96: 635–642
- Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–713
- Jimenez-Genchi A. Immediate switching from moclobemide to duloxetine may induce serotonin syndrome. J Clin Psychiatry 2006; 67: 1821–1822
- Strouse T, Kerrihard TN, Forscher CA, et al. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psychopharmacology 2006; 26: 681–683
- Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaprine with other serotonergic drugs. Anesth Analg 2006; 103: 1466–1468